Fasken | Canada | 23 Jan 2024
This bulletin provides an update on the most recent decision of the Federal Court in the ongoing saga concerning Galderma's dermatology medicine…
Fasken | Canada, USA | 17 Jan 2024
On January 5, 2024, the U.S. Food and Drug Administration (FDA) signed off on Florida’s request to import prescription drugs from Canada under the…
Arogya Legal | India | 3 Jan 2024
The Export Inspection Agency under the Department of Commerce will henceforth issue health certificate to milk and milk product exporters only when…
Harris Sliwoski LLP | USA | 18 Oct 2022
The U.S. Court of International Trade (“CIT”) issued a recent opinion that indicates the import or export of “drug paraphernalia” to or from states…
Lexology PRO | European Union, United Kingdom | 5 Aug 2021
The UK’s Competition and Markets Authority has accused Pfizer and Flynn Pharma of charging unfairly high prices for an anti-epilepsy medication, 17 months after an appellate court ordered the agency to redo parts of its initial probe into the drugmakers.
Lexology PRO | United Kingdom | 29 Jul 2021
The UK’s Competition and Markets Authority has hit Advanz Pharma and its two former owners with more than £100 million in fines for overcharging the country’s national health service for thyroid medication liothyronine over an eight-year period.
Lexology PRO | European Union, Italy, Netherlands, etc. | 19 Jul 2021
The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
Dykema Gossett PLLC | USA | 2 Apr 2019
On April 2, 2019 the FDA further described its upcoming effort to regulate or at least discuss the regulation of cannabis-containing and…
Morgan, Lewis & Bockius LLP | USA | 8 Mar 2019
The US Food and Drug Administration (FDA or Agency) on January 30 signaled what could be an about-face with regard to its role administering the List…
Jones Day | USA | 31 Jan 2019
Mylan Pharmaceuticals, Inc. petitioned for inter partes review (IPR) of U.S. Patent No. 6,858,650 (the “‘650 Patent”), which is owned by UCB Pharma…